Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.
05-04-2023

AstraZeneca shot raised heart-related death risk in young women: Report

 AstraZeneca's Covid vaccine (manufactured and administered in India as Covishield) raised the risk of heart problem, and death by 3.5 times in young women in the first three months following
30-03-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window

 This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, read with AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Equity Shares of the Company will be closed from March 16, 2023 and the same shall reopen after 48 hours from the declaration of Audited Financial Results of the Company for the quarter and year ending March 31, 2023. We request you to please take the same on record.
14-03-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.
06-03-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith the Certificate dated March 3, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Please take the same on record.
06-03-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Clarification Of Inadvertent Typographical Error With Respect To The Intimation Of Declaration Of Voting Results Of Postal Ballot Along With The Scrutinizer'S Report Dated February 28, 2023

 This is in continuation to our letter dated February 28, 2023, wherein it was stated that the Company has referred to its letter dated February 25, 2023, enclosing therewith Postal Ballot Notice dated February 24, 2023 seeking consent of the Members of the Company through Special Resolutions. In the said communication, in place of letter dated February 25, 2023 it should be read as January 25, 2023 and in place of Postal Ballot Notice dated February 24, 2023 it should be read as Postal Ballot Notice dated January 24, 2023. This was most inadvertent typo error please. The intimation of Declaration of Voting results of Postal Ballot along with the Scrutinizer's Report dated February 28, 2023 should be read in continuance with this clarification letter. Further, the enclosures to our letter dated February 28, 2023 shall remain unchanged. We regret the inconvenience caused and request you to kindly take the above intimation on record.
02-03-2023
Bigul

AstraZeneca expands its portfolio by bringing rare disease therapy in India

 AstraZeneca aims to address the severe unmet needs of patients living with rare diseases and transform their quality of life
28-02-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Declaration Of Voting Results Of Postal Ballot Along With The Scrutinizer'S Report

 This is in reference to our letter dated February 25, 2023, enclosing therewith a Postal Ballot Notice dated February 24, 2023 seeking consent of the Members of the Company through Special Resolutions for Reappointment of Mr. Rajesh Marwaha (DIN: 01458768) as Whole Time Director of the Company and Appointment of Mr. Sanjeev Kumar Panchal (DIN: 09823879) as Director and also as Managing Director of the Company. Pursuant to Regulation 44 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform that the said Resolutions has been passed by the Members of the Company with requisite majority. We are enclosing herewith the Voting Results along with the Scrutinizer's Report and the same are being placed on the Company's website at http://www.astrazeneca.com/india and website of National Securities Depository Limited at www.evoting.nsdl.com.
28-02-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Authorised Key Managerial Personnel To Determine Materiality Of Events/Information

 Please find the enclosed letter of the Company pertaining to the captioned subject for your reference.
24-02-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimants.
24-02-2023
Next Page
Close

Let's Open Free Demat Account